Market Cap (In CNY)
2.2 Billion
Revenue (In CNY)
667.03 Million
Net Income (In CNY)
15.38 Million
Avg. Volume
3.73 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.57-13.62
- PE
- -
- EPS
- -
- Beta Value
- 0.339
- ISIN
- CNE100002C39
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Ke Xu
- Employee Count
- -
- Website
- https://www.emyy.cn
- Ipo Date
- 2016-12-12
- Details
- Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
More Stocks
-
JMJFINJMJ Fintech Limited
JMJFIN
-
BDULF
-
VESTUMVestum AB (publ)
VESTUM
-
EMFGF
-
SSRMSSR Mining Inc.
SSRM
-
FRONTCORPFrontline Corporation Limited
FRONTCORP
-
MRES
-
PTKFFPT Kalbe Farma Tbk.
PTKFF